Relacionar Columnas Diabetes Oral MedsVersión en línea NUr115 Oral Diabetic Agents por Concetta Fiorentino 1 Prevents kidneys from reabsorbing glucose. 2 Enhances glucose-dependent insulin secretion. 3 Sensitize body tissue to insulin: stimulates insulin receptor sites. 4 Stimulate beta cells of the pancreas. 5 Usually given once a day. 6 Inhibit production of glucose by the liver. 7 Stimulate pancreas to secrete insulin. 8 Do not increased insulin secretion. 9 Possible side-effect of impaired platelet function. 10 Drug to drug interaction with NSAIDS. 11 Increase and prolong the action of the hormone that increases insulin release and decreases glucagon levels. Glucagon-like peptide-1 agonist (liraglutide/Victoza,, dulaglutide/Trulicity) Thiazolidinediones (pioglitazone (actos, rosiglitazone/Avandia) Non-sulfonylurea insulin secretagogues (repaglinide/Prandin, nateglinide/Starlix) Biguanides (metformin (Glucophage) Metformin with glyburide (Glucovance) Sodium-glucose co-transporter 2 inhibitors (empagliflozin/Jardiance Second generation sulfonylureas (glipizide (Glucotrol) Glyburide (DiaBeta) Glimepiride (Amaryl) Avandia Dipeptidyl Pepidase-4 Inhibitors (sitagliptin/Januvia, vildagliptin /Galvus) Alpha-glucosidase inhibitors (acarbose/Precose, miglitol (Glyset) Januvia glipizide
Crear